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Background: Using quantitative methylation-specific PCR (QM-MSP) is a promising method for colorectal cancer
(CRC) diagnosis from stool samples. Difficulty in eliminating PCR inhibitors of this body fluid has been extensively
reported. Here, spermidine is presented as PCR facilitator for the detection of stool DNA methylation biomarkers
using QM-MSP. We examined its effectiveness with NPY, PENK and WIF1, three biomarkers which we have previously
shown to be of relevance to CRC.
Results: We determined an optimal window for the amplification of the albumin (Alb) gene (100 ng of bisulfite-treated
stool DNA added of 1 mM spermidine) at which we report that spermidine acts as a PCR facilitator (AE = 1680%) for SG
RT-PCR. We show that the amplification of methylated PENK, NPY and WIF1 is considerably facilitated by QM-MSP as
measured by an increase of CMI (Cumulative Methylation Index, i.e. the sum of the three methylation values) by a factor
of 1.5 to 23 fold in individual samples, and of 10 fold in a pool of five samples.
Conclusions: We contend that spermidine greatly reduces the problems of PCR inhibition in stool samples. This
observed feature, after validation on a larger sampling, could be used in the development of stool-based CRC diagnosis
tests.
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Colorectal cancer (CRC) is one of the most common forms
of cancer in the world [1]. CRC can be cured if diagnosed
at early stage using endoscopic examination [2,3], making
early non-invasive screening a crucial aim. The develop-
ment of CRC results from the progressive accumulation of
genetic and epigenetic alterations leading to the transform-
ation of normal colonic epithelium to colon adenocarcin-
oma [4-6]. Fecal-occult blood test (FOBT) is the most
widely used method of screening for CRC [7,8]. However,
FOBT lacks sensitivity as well as specificity for screening
an average risk population. Epigenetic alterations have
been found frequently in neoplastic diseases [9,10]. It has
been reported that the analysis of DNA methylation car-
ried out in body fluids represents a valuable source for the
discovery of cancer biomarkers [11]. Prior studies showed* Correspondence: roperch@oncodiag.fr
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unless otherwise stated.that the hypermethylation can be detected in tumor-
derived DNA found in the serum [12-14] and stool [14-17]
of patients with CRC. More recently, we proposed a panel
of three hypermethylated genes (NPY, PENK and WIF1) as
potential biomarkers for the early diagnosis of CRC in tis-
sue and blood samples, based on QM-MSP assay [18].
However, these studies show that the sensitivity of detec-
tion must be improved for the application in diagnostic
routine. For this reason, the analysis of aberrant methyla-
tion in stool DNA might provide a novel strategy for early
detection of CRC. The Ahquist’s team demonstrated that
blood invasion is more common in advanced stages of
CRC where an earlier exfoliation of adenoma and/or tumor
cells into the colonic lumen [19]. Moreover, Davies RJ and
colleagues showed that the number of colonocytes in the
stool following exfoliation from malignant lesions is about
4–5 fold greater than from normal tissue [20] with a mean
concentration of 100 ng/g stool, corresponding to 0.01% of
the total DNA [21]. However, the composition of feces is
highly complex including PCR inhibitors (i.e., bile salts andl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inhibitors can dramatically reduce the sensitivity and amp-
lification efficiency of PCR [22]. As a consequence, consist-
ent extraction of high-quality DNA from fecal samples can
be quite challenging, because of the presence of PCR inhib-
itors that are co-extracted with DNA. Spermidine is a poly-
amine that has previously been reported to facilitate stool
DNA amplification by inhibiting PCR inhibitors [23,24].
Here, we investigated the stimulating effect of spermi-
dine as PCR facilitator for detecting tumor-specific meth-
ylated markers in stool DNA.
Results
Using the Alb gene to test PCR specificity to bisulfite
sequencing; checking about absence of interference with
PCR ampilication of the NPY, PENK and WIF genes
We performed bisulfite sequencing of the entire amplifi-
cation products in presence and absence of spermidine
using nucleic sequences obtained from the albumin
(Alb) gene (data not shown). In Figure 1A, we have rep-
resented the sequencing electrophoregram of the Alb
promoter, as assessed by using SG RT-PCR from C1 and
S1 with 1 mM spermidine. We observed that thymidine
are detected instead of cytosine, as expected after DNA
bisulfite modification of unmethylated amplicon prod-
ucts, since they correspond to a region of Alb which
does not contain CpG sites. Those findings indicate that
all cytosine are converted to thymine as a result of the
DNA modification step being performed successfully
and that the spermidine do not interferes in the specifi-
city of PCR. We also verified that spermidine does notFigure 1 Verification and comparison of PCR amplification products of the al
bisulfite sequencing electrophoregram of the Alb promoter using SG RT-PCR i
(C1) and stool DNA sample (S1). All cytosine are converted to thymine noted i
bisulfite treatment (Bis) when referring to wild-type (WT) Alb gene sequence a
electrophoresis and revealed single amplification fragment of the predicted si
NTC as negative control.interferes the PCR amplification of NPY, PENK and
WIF1 genes into of CpG rich regions (data not shown).
Comparing Alb PCR products with and without utilization
of spermidine
On agarose gel electrophoresis, we observed, in Control
(C) and Sample (S) DNA, the 76 bp band confirming the
existence of Alb gene with or without the presence of
spermidine (data not shown). Figure 1B, shows the DNA
migration from C (C0-C1) and S (S0-S1) with and with-
out 1 mM spermidine addition to the reaction mixture.
As expected, we noted a correspondence between band in-
tensities and Ct values with S0 (Ct = 28.16) and S1 (Ct =
25.11) and not with C0 (Ct = 20.05) and C1 (Ct = 20.11)
(Table 1, 1st serial). The negative template control (NTC)
was negative, indicating that it was not nonspecific primer
binding or contamination using 1 mM spermidine and
also in presence of various concentrations of spermidine,
ranging from 1 mM to 10 mM (data not shown).
Impact of spermidine on the melting curves of PCR
products of Alb gene
In Figure 2 are represented the melting curves of ampli-
cons of the Alb gene using spermidine in SG RT-PCR
from C (Figure 2A) and S (Figure 2B). We highlight in
Figure 2C the melting curves of C and S in presence (C1,
S1) and absence (C0, S0) of 1 mM spermidine. Both, C0
and S0 showed a similar temperature of melting (Tm) of
77.7°C and 77.4°C as expected, while for C1 and S1, we
obtained a Tm near 79.2°C (ΔTm = +1.5°C) and 78.9°C
(ΔTm = +1.4°C), respectively. (The full results arebumin gene in presence and absence of spermidine. A: representative
n presence of 1 mM spermidine from universal methylated human DNA
n red resulting entirely from DNA modification. This follows after sodium
nd B: the same PCR products of the Alb were analysed by agarose gel
ze (76 pb) when spermidine is present (C1, S1) and absence (C0, S0);
Table 1 PCR efficiencies in presence and absence of
spermidine
1st experiment Sperm. Ct ΔCt AE (%) Effects ?
1st serial
Control 0 20.05 ± 0.17 100
1 20.11 ± 0.02 0.06 96 =
2 20.77 ± 0.17 0.72 61 -
3 21.12 ± 0.03 1.07 48 -
4 21.70 ± 0.32 1.65 32 -
5 22.66 ± 0.16 2.61 16 -
10 NA ND 0 Total inhibition
Sample 0 28.16 ± 0.85 100
1 25.11 ± 0.11 −3.06 831 +
2 25.35 ± 0.03 −2.81 701 +
3 25.73 ± 0.11 −2.44 541 +
4 26.53 ± 0.16 −1.63 310 +
5 28.08 ± 0.13 −0.08 106 +
10 NA ND 0 Total inhibition
2nd serial
Control 0 19.86 ± 0.33 100
0.05 19.61 ± 0.10 −0.25 119 +
0.10 19.78 ± 0.13 −0.09 106 +
0.50 19.87 ± 0.15 0 100 =
1 19.91 ± 0.14 0.05 97 =
Sample 0 28.17 ± 0.26 100
0.05 26.63 ± 0.49 −1.54 290 +
0.10 25.98 ± 0.11 −2.19 456 +
0.50 25.09 ± 0.01 −3.08 843 +
1 25.22 ± 0.11 −2.95 773 +
Abbreviations: Sperm., spermidine (mM); Ct, mean of cycle threshold value ±
standard deviation value; AE, amplification efficiency; NA, non amplification;
ND, not determined; =, equal; −, inhibitor; +, facilitator.
The amplification efficiency of the albumin gene at each spermidine concentration
points was calculated using 2-ΔCt where ΔCt = (Ct with spermidine) – (Ct without
spermidine). For example in the 1st study, Control DNA with 1 mM of spermidine
showing a ΔCt = 0.06, we recovered 96% of the true yield (100%, ΔCt = 0).
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Table S1).
Checking about PCR inhibition of Alb gene when adding
spermidine at different concentration
We tested different concentrations of spermidine, ranging
from 1 mM to 10 mM (1st serial) and 0.05 mM to 1 mM
(2nd serial). In Figure 3 are represented the amplification
curves of Alb gene (1st serial) illustrating the observed
efficiency-Ct shift relationships using spermidine in SG
RT-PCR from C (Figure 3A) and S (Figure 3B). In Table 1,
the observed result is that low concentrations of spermi-
dine have opposite effects on PCR efficiency of C and S,
with a negative effect on C and a positive effect or PCRfacilitator on S, (we hypothetise that this effects depend
on the purity of DNA samples, assuming C more pure
than S) while an excess of spermidine (10 mM) inhibits
amplification and this regardless of the nature of DNA.
Taken together, those findings suggest that the addition of
1 mM spermidine during PCR cycling might be an
optimum for obtaining the highest amplification efficiency
on C with for both studies AE = 800 ± 39% (ΔCt = −3.00)
of the true yield (AE = 100%, ΔCt = 0 without spermidine)
on the detection of Alb gene. No significant difference was
found on control with AE = 96 ± 0.7% (ΔCt = +0.06). Ex-
ceeding 10 mM of spermidine leads to PCR inhibition.
Varying stool concentration and spermidine concentration
The results are shown in Table 2. They suggest that the
1 mM spermidine together with 100 ng of S DNA provides
an optimal amplification efficiency condition, with AE
amounting to 1680%.
Measuring promoter methylation of NPY, PENK, and WIF1
The results are shown in Table 3. We evaluated in tripli-
cate assays the performance of QM-MSP to quantify the
methylation levels of NPY, PENK, and WIF1. For co-
amplifying two methylation-specific DNA targets in real-
time, we used the associations of Fam-Alb/Vic-WIF1
and Ned-NPY/Vic-PENK. QM-MSP were performed
from ID1 to ID5 plus S (100 ng) and C (50 ng) with (+)
and without (−) the addition of 1 mM spermidine and the
methylation percentage was determined by the 2-ΔΔCt
method. We summarize the results by using the cumula-
tive methylation index (CMI), which is the sum of the
three values. As indicated in Table 3, the results suggest
that the addition of spermidine to the PCR mixture allows
a sensitive analysis of DNA methylation biomarkers, rela-
tive to that not containing spermidine (e.g., on S, the CMI
is 4.65 ± 0.67% with (+) and 0.51 ± 0.12 with (−), respect-
ively and reflects a near 10-fold factor of CMI (P < 0.01,
Student-test)). Furthermore, when we do not observe
amplification both in the presence or absence of spermi-
dine, the most likely hypothesis is that the promoter re-
gion of this gene is unmethylated (e.g., NPY gene from
ID 3).
Discussion
Detection of precancerous and early-stage CRC is cen-
tral to improving patient prognosis. Noninvasive colon
cancer screening by testing feces for the presence of oc-
cult blood still shows poor sensitivity. Consequently, a
number of assays for detection of cancer-specific DNA
alterations from fecal DNA have been proposed as a
new approach for screening and detecting early-stage
colon cancer [25-27].
PCR is a powerful technique for the detection of target
DNA, but its application to stool specimens is always
























































































Figure 2 Comparison of melting curves of amplicons of the Alb gene using spermidine. We used a mixture of primers to amplify Alb gene with
an amount of 50 ng of DNA templates at various spermidine concentrations ranging from 0 up to 10 mM. Melting curves of products are shown
from C (A) and S (B), respectively. In (C), we highlight the melting curves of C and S in presence (C1, S1) and absence (C0, S0) of 1 mM spermidine.
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bile salts, hemoglobin degradation product, and complex
polysaccharides), that are known to often inhibit PCR
[28-30]. Problems in eliminating PCR inhibitors from
stool specimens have been extensively reported and, for
many situations, dilution of inhibited samples proves
necessary to provide a rapid and straightforward way of
permitting amplification [31]. However, dilution is only
possible if the amount of DNA is sufficiently high.
Hence, for applications involving low-copy targets and
in presence of high background (i.e., bacterial DNA),
the dilution solution is often undesirable, and indeed
sometimes impossible, due to the further reduction
of already reduced target amount [32,33]. Others
methods have been used to alleviate the effects of in-
hibitory substances of PCR, such as the use of separ-
ation columns. They present a number of problems
too, ranging from reduced DNA yields, leading to de-
crease DNA targets, to decreased amplification cap-
acity [34-36], and for all these reasons, we have not
chosen these methods.Spermidine, a polyamine compound, has been reported
to have a high affinity for plant and stool DNA and could
be used as PCR facilitators by its addition to the reaction
mixture during the PCR steps [23,24].
In the present study, spermidine concentrations were
tested to alleviate PCR inhibition associated with DNA
isolated from stool samples. For the first time, we showed
that spermidine can act both as an activator on stool DNA
or PCR inhibitors on a high purity DNA. Indeed, we
showed that, at increasing concentrations, we have 1) on
DNA samples extracted from stool: increasing efficiency
up to an optimum reached at about 1 mM and then de-
creasing up to total inhibition and 2) on a set of highly
pure DNA: same as 1), but with optimum reached at a
much lower concentration, namely 0.05 mM. (We have no
explanation for the former.) The hypothesis is that spermi-
dine can block the action of PCR inhibitors (possibly by
binding them and or making them more thermolabile, or,
alternatively, that by binding DNA at low concentrations
it can drastically decrease the action of the PCR inhibi-
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Figure 3 Interference of PCR amplification by spermidine. From 50 ng of DNA, the amplification curves of PCR products of the Alb gene using
spermidine in SG RT-PCR are shown from C (A) and S (B). The spermidine has been used at various concentrations, ranging from 1 mM to 10 mM.
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centration threshold above which spermidine no longer
blocks PCR inhibitors, may be due to steric effects or sat-
uration, and starts massively binding to DNA, so inhibit-
ing PCR.
Interesting, we observed that the addition of spermi-
dine causes a positive shift of the melting temperature of
the stool and control DNA. This observation may be
due to the interaction of the spermidine with DNA as it
has been described previously by Ahokas and Erkkila
[23]. We have determined a range of spermidine concen-
trations that counteract the PCR inhibitors co-extracted
with DNA, so facilitating the amplification efficiency of
methylation markers. We applied that finding to asses-
sing the methylation of NPY, PENK, and WIF1, (whose
detection is of interest in CRC, as shown in [17]) while
maintaining sufficient DNA yield. We showed the ad-
vantage of our method in the quantification of methyla-
tion values of CRC markers NPY, PENK and WIF1,
where, on undiluted stool DNA (100 ng) and by using
the QM-MSP in presence of 1 mM spermidine, we glo-
bally enhanced detection by a near 10-fold factor, as
assessed by summing up the three values. In the future,it would be interesting to evaluate our method with
other biomarkers such as Septin 9, which is used as a
marker of blood-based methylation requiring improved
accuracy for a clinical practise [12].
In summary, we performed a comparative study on
the effect of spermidine onto PCR efficiency reporting
that spermidine addition is easier and more useful than
dilution or purification methods and that it can dramat-
ically improve the quantification of methylation values.
We also highlighted a possible mechanism for its action.
Our QM-MSP using the presence of 1 mM spermidine
and 100 ng of stool DNA could be used as a potential
PCR facilitator for stool-based detection of CRC. Our
methodology is also a serious candidate for being devel-
oped into a robust technology, as it has been optimized
with several primer pair and reaction buffer.
Conclusions
In this study, we present a proof of principle for using
spermidine to allow alleviation of the PCR inhibitors fre-
quently encountered in DNA amplification from stool
samples. We also demonstrated that spermidine, an in-
expensive chemical, is useful for sensitive stool-based
Table 2 Relationship between spermidine concentration
and amount of stool DNA
Sperm. Ct ΔCt AE (%)
2nd experiment
50 ng 0 28.32 ± 0.15 100
0.5 25.04 ± 0.11 −3.28 968
1 25.23 ± 0.17 −3.09 849
5 28.39 ± 0.21 0.07 95
100 ng 0 27.04 ± 0.16 100
0.5 23.74 ± 0.12 −3.31 988
1 22.97 ± 0.24 −4.07 1680
5 25.49 ± 0.17 −1.55 293
250 ng 0 NA ND ND
0.5 28.67 ± 0.27 ND ND
1 23.70 ± 0.37 ND ND
5 23.65 ± 0.10 ND ND
500 ng 0 NA ND ND
0.5 NA ND ND
1 28.00 ± 0.56 ND ND
5 26.92 ± 0.30 ND ND
Abbreviations: Sample, stool DNA pooled; Sperm, spermidine (mM); Ct, mean
of cycle threshold value ± standard deviation value; AE, amplification efficiency;
NA, non amplification; ND, not determined.
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mors using QM-MSP. These results, after corroboration
in a large cohort, can lead to the elaboration of a
method to be used in clinical practice as a aid in prese-
lecting the patients for colonoscopy.Table 3 Quantitative DNA methylation analysis
Methylation (%) CMI (%)
3rd experiment NPY PENK WIF1
ID1 - 0.01 ± 0.01 0.13 ± 0.03 NA 0.14 ± 0.04
+ 0.86 ± 0.26 1.10 ± 0.08 1.22 ± 0.41 3.18 ± 0.75
ID2 - 1.22 ± 0.21 1.31 ± 0.53 0.07 ± 0.18 2.60 ± 0.92
+ 1.86 ± 0.11 1.35 ± 0.09 0.76 ± 0.15 3.97 ± 0.35
ID3 - NA NA 0.17 ± 0.07 0.17 ± 0.07
+ NA 0.10 ± 0.04 1.59 ± 0.22 1.69 ± 0.26
ID4 - 0.17 ± 0.08 0.32 ± 0.10 NA 0.49 ± 0.18
+ 2.33 ± 0.32 1.88 ± 0.44 1.71 ± 0.27 5.65 ± 0.67
ID5 - 0.09 ± 0.08 0.17 ± 0.05 0.07 ± 0.01 0.33 ± 0.14
+ 1.33 ± 0.22 1.44 ± 0.16 1.01 ± 0.07 3.78 ± 0.45
Sample (pooling - 0.21 ± 0.06 0.27 ± 0.06 0.03 ± 0.03 0.51 ± 0.12
of five patients) + 1.74 ± 0.30 2.10 ± 0.18 0.81 ± 0.1 4.65 ± 0.67Methods
Human stool samples
We analyzed human stool samples from 5 colonoscopy-
negative subjects from the Valihybritest’s collection, regis-
tered under the number NCT01270360 (Clinical Trials.
gov). All of the patients provided informed consent for
the research use of their samples.
Use of these samples for this study was approved by the
ethical committee of the Val de Marne Paris-Est medical
district, registered under code CCP-IDF-IX-11-010.Experimental design
This study included three related experiments: the first
experiment was designed to study the interference of
PCR amplification by spermidine addition at various
concentrations ranging from 0.05 mM to 10 mM both
50 ng of universal methylated DNA (Control, C) and
50 ng of stool DNA pooled (Sample, S), each DNA pre-
viously modified by sodium bisulfite. The second experi-
ment determined the optimum condition giving the best
performance of PCR amplification by modulating both
the amount of stool DNA (from 50 ng to 500 ng of
modified DNA) and the concentration of spermidine
(from 0.5 mM to 5 mM). In these studies, we used
spermidine-containing reaction solutions to assess the
amplification of the albumin (Alb) gene using SYBER
Green real-time PCR (SG RT-PCR). In the third experi-
ment, the quantitative methylation-methylation specific
PCR (QM-MSP) was performed, with the optimum con-
dition previously defined in 1st and 2nd experiments, to
measured the degree of methylation of a three-gene
panel consisting of NPY, PENK, and WIF1 and calcu-
lated the cumulative methylation index (CMI) value of
each extract of stool DNA, i.e., ID 1 to ID 5 and Sample.Stool DNA isolation and quantification
About 5 g stool were collected from each individual.
DNA was isolated from stool samples (200 mg) using
the QiAamp DNA stool mini kit (Qiagen) according to
the manufacturer’s protocol. DNA concentrations were
determined by measurement at 260 nm using BioPho-
tometer (Eppendorf ). Isolated DNA was stored at −20°C.Bisulfite modification
1 μg of each DNA (C and S) were modified by sodium
bisulfite overnight at 50°C using the EZ DNA Methyla-
tion kit (Zymo Research) and eluted in 100 μl of TE
buffer (10 mM Tris–HCl (pH 8.0), 1 mM EDTA). Bisul-
fite treatment converts all unmethylated cytosine resi-
dues to uracil (later replicated as thymidine during PCR
cycling), while leaving methylcytosines unchanged.
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For SG RT-PCR, the primers targeting the albumin (Alb)
gene were reported in Table 1. PCR reactions specific for
the Alb gene promoter region, which not containing
CpG sites. For QM-MSP analysis we used the same
primers as those described using SG RT-PCR with in
addition the probes targeting Alb as Control gene, NPY,
PENK and WIF1 as CRC-specific genes were reported
previously [17] (Additional file 2: Table S2). Primers and
probes are designed by Life Technologies company.
Quantitative real-time PCR analysis
All PCR reactions were carried out in a 96-well reaction
plate in a StepOne Plus Real-Time PCR system (Life
Technologies) in a final volume of 20 μl. We used the
universal methylated human DNA standard (Zymo Re-
search) and positive control (Control) and stool DNA as
sample (Sample).
1) SG RT-PCR analysis
Modified DNA was analyzed in duplicate by SYBR-
Green qPCR master mix (Life Technologies) to deter-
mine the optimum concentration of spermidine (Sigma
Aldrich), based on albumin amplification product as it ac-
cumulates during real-time PCR. The range of spermidine
tested is from 50 μM to 10 mM. Five hundred nM of
primers (forward and reverse) were also present. The ther-
mal cycling conditions included an initial denaturation at
95°C for 10 min followed by 48 cycles (95°C for 15 s and
60°C for 1 min). The melting curve was determined by
heating the PCR product from 60°C to 95°C and monitor-
ing the fluorescence at a transition rate of 0.5°C. The melt-
ing temperature or Tm was calculated using the StepOne
plus software (Life Technologies), based on the initial
fluorescence curve by plotting the negative derivative of
fluorescence-reporter (−Rn) over temperature versus
temperature (−Rn/T).
2) QM-MSP analysis
QM-MSP was performed in triplicate to detect and
quantify simultaneously three methylated markers in
control and DNA sample using the TaqMan MBG
probes technology (Life Technologies). We chose this
technique because it allows accurate quantitative assess-
ment of DNA methylation. For each PCR run, a KAPA
PROBE master mix (Kapa Biosystems) was prepared,
spermidine (1 mM, used as optimum concentration),
primers (500 nM) and probes (250 nM) for Alb, WIF1,
NPY and PENK have been designed (Life Technologies).
For co-amplifying two methylation-specific DNA targets
in QM-MSP, we used the combinations of Fam/Vic and
Ned/Vic fluorophores probes as each probe presents a
strong individual spectral intensity with limited overlap-
ping absorption spectra. The PCR cycling parameters wereinitial denaturation at 95°C for 10 min followed by 95°C
for 15 s, 60°C for 1 min, repeated 48 times.Bisulfite genomic sequencing
The PCR products of albumin gene were purified before
submission to the sequencing process of both strands by
using BigDye Terminator Cycle Sequencing kit (Life
Technologies) according to the manufacturer’s instruc-
tions. The sequence reactions were run and analyzed on
an ABI 3100 Genetic Analyzer (Life Technologies). Se-
quence analyses were performed using ChromasPro soft-
ware (Technelysium).DNA electrophoresis
Five microliters of each reaction were run on conven-
tional 2.5% agarose gel electrophoresis with ethidium
bromide (0.5 μg/ml) in TAE buffer (40 mM Tris-Acetate
(pH 8.3), 2 mM EDTA). Electrophoresis was done for
2 h in electric field strength of 40 V/cm gel and the
DNA was visualized under UV light-transilluminator
light (Bio-Rad). The GeneRuler 100 bp DNA ladder
(Fermentas) was run on each gel to estimate the size of
the PCR products.Amplification efficiency measurement
For simplicity, the value (AE) is referred to in the text as
amplification efficiency, with any deviations from 100% due
to the effects of PCR inhibitors or facilitators in the tem-
plate DNA (Control and Sample). The Ct of each reaction
was yielded by StepOne plus System (Life Technologies)
using the amplification-based threshold-determination al-
gorithm; shifts Ct (ΔCt) were measured as the difference
between the average Ct template (with spermidine) and the
average Ct template (without spermidine). To quantify the
inhibition and facilitation effects, we calculated the (AE)
value, where AE = 2-ΔCt × 100%.Calculation of the methylation percentage
The level of methylation (percentage of methylated ref-
erence (PMR)) is quantified according to the calculation
of delta-delta Ct (ΔΔCt). We calculate the PMR of each
gene by taking 2-ΔΔCt as described see below.
ΔΔCt = [(Ct target, Sample)-(Ct ref, Sample)]-[(Ct target,
Control)-(Ct ref, Control)] where:
Ct target, Control = Ct value of gene of interest in con-
trol DNA
Ct ref, Control = Ct value of reference gene in control
DNA
Ct target, Sample = Ct value of gene of interest in
tested sample
Ct ref, Sample = Ct value of reference gene in tested
sample
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